Ascendis Pharma A/S (ASND) reported disappointing financial results for the third quarter of fiscal 2025. The company posted an earnings per share (EPS) of $-1.01, which fell short of Wall Street's consensus estimate of $-0.22 by $0.78. Revenue matched expectations at $0.2 billion but did not exceed them.
This update provides insight into Ascendis Pharma's recent operational performance and financial health. The company is engaged in the development of drug candidates for various medical conditions, including growth hormone deficiency and central nervous system disorders. As of November 8, 2025, Ascendis Pharma holds a market capitalisation of $12.1 billion, with a trailing twelve-month EPS of $-4.55.
Management will host an earnings conference call after market close to discuss these results and provide further commentary on business performance. Investors are encouraged to review the full earnings release and listen to management's insights for a comprehensive understanding of the quarter's performance and future outlook.
Upcoming earnings are scheduled for April 29, 2026, and August 5, 2026, with estimated EPS of $0.49 and $0.81, respectively, alongside revenues of $269.8 million and $300.2 million.